Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company reported $64.6M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE